Proteomics uncover EPHA2 as a potential novel therapeutic target in colorectal cancer cell lines with acquired cetuximab resistance

BACKGROUND: In metastatic colorectal cancer (mCRC), acquired resistance against anti-EGFR targeted monoclonal antibodies, such as cetuximab (CET), was shown to be frequently caused by activating alterations in the RAS genes KRAS or NRAS. To this day, no efficient follow-up treatment option has emerg...

Descripción completa

Detalles Bibliográficos
Autores principales: Torlot, Lucien, Jarzab, Anna, Albert, Johanna, Pók-Udvari, Ágnes, Stahler, Arndt, Holch, Julian Walter, Gerlinger, Marco, Heinemann, Volker, Klauschen, Frederick, Kirchner, Thomas, Kumbrink, Jörg, Küster, Bernhard, Jung, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article – Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9931833/
https://www.ncbi.nlm.nih.gov/pubmed/36401637
http://dx.doi.org/10.1007/s00432-022-04416-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9931833/
https://www.ncbi.nlm.nih.gov/pubmed/36401637
http://dx.doi.org/10.1007/s00432-022-04416-0

Ejemplares similares